Results 101 to 110 of about 2,285,924 (374)

Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning

British Journal of Clinical Pharmacology, EarlyView.
Aims In haematopoietic cell transplantation (HCT), neutropenia resulting from myelosuppression is an expected endpoint following busulfan‐based conditioning. However, if prolonged, neutropenia can lead to complications like serious infection and death.
Beth Apsel Winger, Joseph W. Polli, Janel Long‐Boyle, Andrew Weber, Jordan Brooks, Jaimit Parikh, Valeriu Damian   +6 more
wiley   +1 more source

Emerging Therapies for the Myelodysplastic Syndromes

Clinical Hematology International, 2019
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge.
Jonathan Canaani
doaj   +1 more source

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes [PDF]

, 2013
Background: Myelodysplastic syndromes (MDS) are a group of heterogeneous diseases with variable clinical course. Predicting disease progression is difficult due to lack of specific molecular marker(s).
Chai, Li, Chen, Qian, Cui, Wei, Guo, Ye, Ning, Ning, Tong, Chunrong, Wang, Fei, Xu, Xiaodong, Xu, Yonggang, Yang, Zhuo, Zhang, Yujuan   +10 more
core   +3 more sources

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF).
Abdelrahman Saqr, Shen Cheng, Mahmoud Al‐Kofahi, Christopher Staley, Pamala A. Jacobson   +4 more
wiley   +1 more source

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Haematologica, 2016
Disease relapse is the most common cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, yet treatment options for such patients remain extremely limited.
Charles Craddock, Myriam Labopin, Marie Robin, Juergen Finke, Patrice Chevallier, Ibrahim Yakoub-Agha, Jean Henri Bourhis, Henrik Sengelov, Didier Blaise, Thomas Luft, Michael Hallek, Nicolaus Kröger, Arnon Nagler, Mohamad Mohty   +13 more
doaj   +1 more source

Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome [PDF]

, 2009
Myelodysplastic syndrome (MDS) patients with a normal karyotype constitute a heterogeneous group from a biological standpoint and their outcome is often unpredictable. Interphase fluorescence in situ hybridization (I-FISH) studies could increase the rate
Chauffaille, Maria de Lourdes Lopes Ferrari, Pinheiro, R.f.   +1 more
core   +2 more sources

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Familial myelodysplastic syndromes: a review of the literature

Haematologica, 2011
Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general.
Elena Liew, Carolyn Owen
doaj   +1 more source

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation [PDF]

, 2017
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis.
Alessandrino, E.P., Beelen, D.W. (Dietrich), Biezen, A. (Anja) van, Cahn, J.Y. (J. Y.), Chevallier, P. (Patrice), Cornelissen, J.J. (Jan), Crawley, C. (C.), de Wreede, L.C. (Liesbeth C.), Finke, J. (Jürgen), Göhring, G. (Gudrun), Itälä Remes, M. (Maija), Koenecke, C. (Christian), Kröger, N. (Nicolaus), Ljungman, P., Maertens, J. (Johan), Milpied, N., Mufti, G.J. (Ghulam), Passweg, J. (Jakob Robert), Peniket, A. (A.), Petersen, E.J. (Eefke), Richard Espiga, C. (Carlos), Robin, M. (Marie), Russell, N. (Nigel), Scheid, C. (Christof), Sierra, J. (Jorge), Veelken, J. (Joan), Volin, L. (Liisa), Witte, T. de   +27 more
core   +1 more source

The genetic and molecular pathogenesis of myelodysplastic syndromes

European Journal of Haematology, 2018
Myelodysplastic syndromes (MDS) comprise a diverse group of clonal and malignant myeloid disorders characterized by ineffective hematopoiesis, resultant peripheral cytopenias, and a meaningful increased risk of progression to acute myeloid leukemia.
R. Shallis, R. Ahmad, A. Zeidan
semanticscholar   +1 more source